Phase I trail of temodar plus O6-benzylguanine (O6-BG) (NSC 637037) plus irinotecan (CPT-11) (NSC 616348) in the treatment of patients with recurrent / progressive cerebral anaplastic gliomas

Trial Profile

Phase I trail of temodar plus O6-benzylguanine (O6-BG) (NSC 637037) plus irinotecan (CPT-11) (NSC 616348) in the treatment of patients with recurrent / progressive cerebral anaplastic gliomas

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Benzylguanine; Irinotecan; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2009 Additional investigator identified as reported by ClinicalTrials.gov, last updated 22 Jan 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top